NASDAQ
Allogene Therapeutics, Inc. (ALLO) has a free cash flow growth of 53.18% as of Friday, May 29, 2026. This represents a 1418.18% increase compared to its 12-month average of 3.50%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.